Metagenomi’s (MGX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Metagenomi (NASDAQ:MGX) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

MGX has been the topic of several other research reports. JPMorgan Chase & Co. lowered Metagenomi from an overweight rating to a neutral rating and dropped their price objective for the stock from $16.00 to $6.00 in a report on Thursday, May 2nd. Wells Fargo & Company assumed coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They issued an overweight rating and a $25.00 price target for the company. Jefferies Financial Group began coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They issued a buy rating and a $23.00 price objective on the stock. TD Cowen initiated coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an outperform rating for the company. Finally, BMO Capital Markets assumed coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They set an outperform rating and a $22.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $17.83.

Metagenomi Trading Up 3.1 %

Shares of MGX traded up $0.21 during midday trading on Wednesday, reaching $7.01. The stock had a trading volume of 53,718 shares, compared to its average volume of 164,180. The business has a fifty day moving average price of $9.03. Metagenomi has a 1-year low of $5.50 and a 1-year high of $12.74.

Institutional Trading of Metagenomi

A number of large investors have recently bought and sold shares of MGX. Vanguard Group Inc. acquired a new position in Metagenomi during the 1st quarter worth approximately $1,894,000. Hhlr Advisors LTD. bought a new position in Metagenomi during the first quarter worth about $8,205,000. Altitude Crest Partners Inc. acquired a new position in Metagenomi in the 1st quarter valued at $1,407,000. Finally, Resolute Advisors LLC acquired a new stake in Metagenomi in the first quarter valued at about $106,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.